English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Johnson & Johnson
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Dec 20, 2019
JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
Press release submission
| Jun 14, 2019
JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
Trending
+
Regulatory
Patient Daily News Service
| Jan 22, 2025
National Pharmacists Group to DOGE: Start search for 'waste and inefficiencies in federal programs' with the pharmacy benefit managers
+
Pharmaceuticals
Patient Daily
| Jan 17, 2025
Understanding symptoms and treatment options for long-term effects of COVID-19
+
Regulatory
Patient Daily News Service
| Jan 16, 2025
FTC Chair: Report Finds 'Three Major Pharmacy Benefit Managers Hiked Costs for a Wide Range of Lifesaving Drugs, Including Medications to Treat Heart Disease and Cancer'
